MAB8612
Anti-Varicella-Zoster Virus Antibody, Glycoprotein I
Chemicon®, from mouse
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352203
eCl@ss :
32160702
Nomenclature NACRES :
NA.41
Produits recommandés
Source biologique
mouse
Niveau de qualité
Forme d'anticorps
purified antibody
Type de produit anticorps
primary antibodies
Clone
monoclonal
Espèces réactives
human
Fabricant/nom de marque
Chemicon®
Technique(s)
immunofluorescence: suitable
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
Isotype
IgG2b
Conditions d'expédition
wet ice
Spécificité
Recognizes the VZV glycoprotein I by indirect immunofluorescence, immuno-precipitation and Western blotting.
Immunogène
Epitope: Glycoprotein I
VZV HZ strain.
Application
Anti-Varicella-Zoster Virus Antibody, Glycoprotein I is an antibody against Varicella-Zoster Virus for use in IF, IP, WB, IH.
Indirect immunofluorescence: on unfixed cells shows both cytoplasmic and membrane pattern. Staining on fixed cells shows only cytoplasmic pattern.
Immunohistochemistry: reactive on formalin fixed tissue.
Western blot
Immunoprecipitation
Optimal working dilutions must be determined by the end user.
Immunohistochemistry: reactive on formalin fixed tissue.
Western blot
Immunoprecipitation
Optimal working dilutions must be determined by the end user.
Research Category
Infectious Diseases
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral
Infectious Diseases - Viral
Forme physique
1 mg/mL in 0.02M PB with 0.25M NaCl, pH 7.6, containing 0.1% sodium azide.
Format: Purified
Stockage et stabilité
Maintain at 2-8°C in undiluted aliquots for up to 12 months.
Informations légales
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Clause de non-responsabilité
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Code de la classe de stockage
10 - Combustible liquids
Classe de danger pour l'eau (WGK)
WGK 2
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Varicella-zoster virus ORF12 protein activates the phosphatidylinositol 3-kinase/Akt pathway to regulate cell cycle progression.
Liu, X; Cohen, JI
Journal of virology null
Hirobumi Saitoh et al.
Internal medicine (Tokyo, Japan), 52(15), 1727-1730 (2013-08-02)
Disseminated visceral varicella-zoster virus (VZV) infection rarely occurs in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT). To date, only a few cases of isolated VZV-induced fulminant hepatitis following allo-HSCT have been reported. We herein describe the case of a
Development of recombinant varicella-zoster viruses expressing luciferase fusion proteins for live in vivo imaging in human skin and dorsal root ganglia xenografts.
Stefan L Oliver, Leigh Zerboni, Marvin Sommer, Jaya Rajamani, Ann M Arvin et al.
Journal of Virological Methods null
Ryo Takahashi et al.
Journal of immunology (Baltimore, Md. : 1950), 192(3), 969-978 (2014-01-01)
It remains unknown why the occurrence of eczema herpeticum (EH) caused by an extensive disseminated cutaneous infection with HSV-1 or HSV-2 is associated with the exacerbation of atopic dermatitis lesions after withdrawal of treatment. Although regulatory T cells (Tregs) limit
Identification of an important immunological difference between virulent varicella-zoster virus and its avirulent vaccine: viral disruption of dendritic cell instruction.
Cindy Gutzeit,Martin J Raftery,Matthias Peiser,Karsten B Tischer,Martina Ulrich et al.
Journal of immunology (Baltimore, Md. : 1950) (1950)
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique